Patients were randomized to receive placebo , cariprazine 1.5 mg/d , cariprazine 3.0 mg/d , cariprazine 4.5 mg/d , or risperidone 4.0 mg/d ( for assay sensitivity ) for 6 weeks of double-blind treatment and 2 weeks of safety follow-up .